Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 10/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30711152 | 1.00 | TSHR (0.55) | TSHRCYP3A4ALDH1A1RECQLTDP1 | |
| SCHEMBL2056614 | 0.85 | TSHR (0.57) | TSHRCYP3A4ALDH1A1RECQLTDP1 | |
| SCHEMBL588286 | 0.83 | TSHR (0.55) | TSHRCYP3A4ALDH1A1RECQLTDP1 | |
| SCHEMBL2656793 | 0.83 | TSHR (0.55) | TSHRCYP3A4ALDH1A1RECQLTDP1 | |
| SCHEMBL938650 | 0.82 | TSHR (0.55) | TSHRCYP3A4ALDH1A1RECQLTDP1 | |
| SCHEMBL3192674 | 0.80 | TSHR (0.65) | TSHRCYP3A4ALDH1A1RECQLTDP1 | |
| SCHEMBL8335528 | 0.80 | TDP1 (0.52) | TSHRCYP3A4ALDH1A1RECQLTDP1 | |
| SCHEMBL899707 | 0.80 | TDP1 (0.52) | TSHRCYP3A4ALDH1A1RECQLTDP1 | |
| SCHEMBL30503599 | 0.79 | TDP1 (0.71) | TSHRCYP3A4ALDH1A1RECQLTDP1 | |
| SCHEMBL9719281 | 0.79 | TDP1 (0.71) | TSHRCYP3A4ALDH1A1RECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| US-20250101038-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-03-27 | — | — | US | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| EP-4452937-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| CN-117255784-A | Heterocyclic compounds capable of activating STING | 勃林格殷格翰国际有限公司 | 2023-12-19 | — | — | CN | disclosed |
| WO-2023180388-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023115166-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| EP-1751136-B1 | NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER | AMGEN INC (US) | 2014-07-02 | — | — | EP | disclosed |
| US-8476434-B2 | Protein kinase modulators and method of use | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | LLINAS-BRUNET MONTSE | 2007-10-18 | — | — | US | disclosed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060009453-A1 | Protein kinase modulators and method of use | AMGEN INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005028501-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-31 | — | — | WO | disclosed |
| EP-0944620-A1 | 2-IMIDAZOLINYLAMINOINDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023609-A1 | 2-IMIDAZOLINYLAMINOINDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| US-4147804-A | ANTIARRHYTHMIA AGENTS | WILLIAM H. RORER, INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4069105-A | FOR ENZYME IMMUNOASSAY AND COMPETITIVE PROTEIN BINDING ASSAY | SYVA COMPANY (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101038-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | TSHR 1561/4885CYP3A4 759/4885ALDH1A1 981/4885 |
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | TSHR 2825/4885CYP3A4 201/4885ALDH1A1 319/4885 |
| US-20060009453-A1 | Protein kinase modulators and method of use | PHKG1, PRKCH, BMP2K | TSHR 1484/4885CYP3A4 2722/4885ALDH1A1 4013/4885 |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | TSHR 2825/4885CYP3A4 201/4885ALDH1A1 319/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | TSHR 1382/4885CYP3A4 1468/4885ALDH1A1 3146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.